Literature DB >> 21181167

[Basic principles, planning and implementation of non-commercial clinical trials].

R P Finger1, C Coch, M Coenen, M Mengel, G Hartmann, F G Holz.   

Abstract

The proof of a drug's efficacy in randomized controlled trials is fundamental to therapeutic concepts determined by evidence-based medicine. Clinical trials according to the German Medicinal Products Act are performed by the pharmaceutical industry as company-sponsored trials (CST) driven by commercial interests or by non-commercial facilities as investigator-initiated trials (IIT), typically implemented by University Hospitals. In areas with no commercial interest, IITs are the driving force that generate scientific progress leading to treatment optimization. Therefore, non-commercial or investigator-initiated clinical trials are indispensable for improving medical care. To ensure the safety of trial participants and the quality of the data obtained, clinical trials are controlled by many legal regulations and internationally accepted quality standards. Therefore implementation of a clinical trial requires profound knowledge, qualified personnel, appropriate infrastructure, and substantial financial resources. In IITs unlike CSTs this has to be accomplished by the University without the assistance of the pharmaceutical industry. Since teaching of skills needed to perform clinical trials is still largely neglected in medical school and during residency this review addresses the (in clinical trials) inexperienced physician and outlines the characterization of a clinical trial, the range and division of responsibilities and the performance of clinical trials according to the German Medicinal Products Act.

Entities:  

Mesh:

Year:  2011        PMID: 21181167     DOI: 10.1007/s00347-010-2310-9

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  19 in total

1.  Evaluation of conflict of interest in economic analyses of new drugs used in oncology.

Authors:  M Friedberg; B Saffran; T J Stinson; W Nelson; C L Bennett
Journal:  JAMA       Date:  1999-10-20       Impact factor: 56.272

Review 2.  Scope and impact of financial conflicts of interest in biomedical research: a systematic review.

Authors:  Justin E Bekelman; Yan Li; Cary P Gross
Journal:  JAMA       Date:  2003 Jan 22-29       Impact factor: 56.272

3.  Institution/investigator-initiated clinical trials in Canada.

Authors:  Jan Sedgeworth; Lidia Derewlany
Journal:  Can J Clin Pharmacol       Date:  2006-07-25

4.  [The Coordinating Centres for Clinical Trials Network. Objectives and significance for research sites].

Authors:  I Bruns; H Maier-Lenz; S Wolff
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2009-04       Impact factor: 1.513

5.  Developing good scientific publishing practices: one pharmaceutical company's perspective.

Authors:  Sherie A Dowsett; Luann E Van Campen; Lisa A Bednar
Journal:  Curr Med Res Opin       Date:  2010-06       Impact factor: 2.580

6.  Evidence based medicine: what it is and what it isn't.

Authors:  D L Sackett; W M Rosenberg; J A Gray; R B Haynes; W S Richardson
Journal:  BMJ       Date:  1996-01-13

Review 7.  Treating children with arthritis: towards an evidence-based culture.

Authors:  Brian M Feldman
Journal:  J Rheumatol Suppl       Date:  2005-01

8.  Patients' health or company profits? The commercialisation of academic research.

Authors:  Nancy F Olivieri
Journal:  Sci Eng Ethics       Date:  2003-01       Impact factor: 3.525

Review 9.  Is ophthalmology evidence based? A clinical audit of the emergency unit of a regional eye hospital.

Authors:  T Y Y Lai; V W Y Wong; G M Leung
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

10.  Evidence-based management of resident-performed cataract surgery: an investigation of compliance with a preferred practice pattern.

Authors:  Elizabeth S Niemiec; Kent L Anderson; Ingrid U Scott; Paul B Greenberg
Journal:  Ophthalmology       Date:  2009-03-05       Impact factor: 12.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.